You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: Neuroene Therapeutics, LLC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Approximatelymillion Americans suffer from asthmawhich leads to aboutdeaths per yearand is responsible for estimated annual total direct and indirect costs of $billionDespite the existing treatments for asthmapredominantly combinations of inhaledagonists and corticosteroidsCSsthere remains a significant unmet medical need for new therapies which address two key issuesapproximatelyof patients are i ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Inhibition of MIF to Improve Glucocorticoid Response

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Abstract Despite the advent of biological therapiesglucocorticoidsGCsremain the most widely prescribed medicines for the management of inflammatory diseases such as lupusasthmamultiple sclerosisand rheumatoid arthritisHoweverlong term and high dose GC use is inevitably accompanied by systemic toxicityThere are no adjunctive therapies that could enhance the disease modifying effects of GCs at low d ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government